This suggests that compounds capable of stimulating the production of endogenous BDNF or the activation of TrkB-receptors in the PFC and hippocampus may be potentially useful for the treatment or prevention of depression and AD via protection of astrocytes. The gene discussed is BDNF; the disease is depressive symptom measurement.